Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
AnaptysBio, Inc.
ANAB
$31.83
Name : AnaptysBio, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $890,380,480.00
EPSttm : -4.39
finviz dynamic chart for ANAB
AnaptysBio, Inc.
$31.83
6.56%
$1.96

Float Short %

36.76

Margin Of Safety %

Put/Call OI Ratio

2.43

EPS Next Q Diff

0.45

EPS Last/This Y

0.24

EPS This/Next Y

-0.43

Price

31.77

Target Price

56.5

Analyst Recom

1.18

Performance Q

22

Relative Volume

1.17

Beta

0.16

Ticker: ANAB




23 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-09-08ANAB22.191.431.216187
2025-09-09ANAB22.111.440.256275
2025-09-10ANAB22.731.430.006287
2025-09-11ANAB23.211.440.366272
2025-09-12ANAB23.421.450.436263
2025-09-15ANAB20.931.450.356265
2025-09-16ANAB19.421.450.426537
2025-09-17ANAB19.811.469172932330856568
2025-09-18ANAB21.071.471.256573
2025-09-19ANAB20.851.470.476580
2025-09-22ANAB21.391.310.185972
2025-09-23ANAB20.931.310.005991
2025-09-24ANAB22.141.310.005996
2025-09-25ANAB22.051.310.005996
2025-09-26ANAB23.541.315.005995
2025-09-29ANAB23.311.310.006001
2025-09-30ANAB30.621.314.876006
2025-10-01ANAB31.981.691.577137
2025-10-02ANAB31.261.769.167285
2025-10-03ANAB30.932.431.599724
2025-10-06ANAB30.222.430.049744
2025-10-07ANAB29.842.450.689721
2025-10-08ANAB31.822.430.509737
DateSymbolLastP/C OIP/C VolTotal OI
23 items Current Page1 of 1




23 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-09-08ANAB22.19-36.9-0.4-4.80
2025-09-09ANAB22.09-36.91.4-4.80
2025-09-10ANAB22.75-36.9-2.0-4.80
2025-09-11ANAB23.20-36.9-0.9-4.80
2025-09-12ANAB23.40-36.90.1-4.80
2025-09-15ANAB20.16-36.914.5-4.80
2025-09-16ANAB19.40-36.95.2-4.80
2025-09-17ANAB19.79-36.9-1.3-4.80
2025-09-18ANAB21.06-36.9-6.1-4.80
2025-09-19ANAB20.83-36.92.4-4.80
2025-09-22ANAB21.40-36.9-1.8-4.80
2025-09-23ANAB20.96-36.93.1-4.80
2025-09-24ANAB22.14-36.9-5.2-4.80
2025-09-25ANAB22.04-36.91.4-4.80
2025-09-26ANAB23.58-36.9-6.2-4.80
2025-09-29ANAB23.28-36.92.2-4.80
2025-09-30ANAB30.59-36.9-30.2-4.80
2025-10-01ANAB31.99-36.9-2.9-4.80
2025-10-02ANAB31.29-36.929.4-4.80
2025-10-03ANAB30.96-36.929.0-4.80
2025-10-06ANAB30.28-37.730.0-4.80
2025-10-07ANAB29.84-37.729.1-4.88
2025-10-08ANAB31.77-37.725.4-4.88
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
23 items Current Page1 of 1




23 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-09-08ANAB-1.52-15.7837.50
2025-09-09ANAB-1.52-15.7837.50
2025-09-10ANAB-1.52-15.7837.50
2025-09-11ANAB-1.52-15.7837.89
2025-09-12ANAB-1.52-15.7837.89
2025-09-15ANAB-1.52-15.7937.89
2025-09-16ANAB-1.52-15.7937.89
2025-09-17ANAB-1.52-15.7937.89
2025-09-18ANAB-1.52-15.7937.89
2025-09-19ANAB-1.52-15.7937.89
2025-09-22ANAB-1.52-15.7937.89
2025-09-23ANAB-1.52-15.7937.89
2025-09-24ANAB-1.52-15.7937.89
2025-09-25ANAB-1.52-15.7936.78
2025-09-26ANAB-1.52-15.7936.78
2025-09-29ANAB-1.52-12.1036.78
2025-09-30ANAB-1.52-12.1036.78
2025-10-01ANAB-1.85-12.1036.78
2025-10-02ANAB-1.85-12.1036.78
2025-10-03ANAB-1.85-12.1036.78
2025-10-06ANAB-1.85-12.2436.76
2025-10-07ANAB-1.86-12.2436.76
2025-10-08ANAB-1.86-12.2436.76
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
23 items Current Page1 of 1

Last Quarter Act. EPS

-1.34

Avg. EPS Est. Current Quarter

-1.56

Avg. EPS Est. Next Quarter

-0.89

Insider Transactions

-1.86

Institutional Transactions

-12.24

Beta

0.16

Average Sales Estimate Current Quarter

16

Average Sales Estimate Next Quarter

51

Fair Value

Quality Score

52

Growth Score

38

Sentiment Score

40

Actual DrawDown %

23.1

Max Drawdown 5-Year %

-69.3

Target Price

56.5

P/E

Forward P/E

PEG

P/S

7.24

P/B

P/Free Cash Flow

EPS

-4.48

Average EPS Est. Cur. Y​

-4.88

EPS Next Y. (Est.)

-5.31

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-107.66

Relative Volume

1.17

Return on Equity vs Sector %

271.2

Return on Equity vs Industry %

284.9

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.08

EBIT Estimation

25.4
AnaptysBio, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 136
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
stock quote shares ANAB – AnaptysBio Inc Stock Price stock today
news today ANAB – AnaptysBio Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ANAB – AnaptysBio Inc yahoo finance google finance
stock history ANAB – AnaptysBio Inc invest stock market
stock prices ANAB premarket after hours
ticker ANAB fair value insiders trading